Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Predictmedix AI Inc C.PMED

Alternate Symbol(s):  PMEDF

Predictmedix AI Inc. is a life sciences technology company. The Company, through its subsidiaries, focuses on artificial intelligence (AI) technologies which target two specific areas: workplace health and safety and healthcare. It has developed a technology for the identification and detection of infectious disease symptoms, including COVID-19, referred to as its infectious disease symptom screening solutions (IDSS) and marketed in North America under the name Safe Entry System. It is also developing AI-powered products that address detection of alcohol and/or cannabis impairment in individuals; mental illness screening, and remote patient monitoring and treatment plans, referred to as the Mobile Wellbeing product. It is adding additional modules to this Mobile Wellbeing platform that enable us to use a patient’s history and real-time medical data, such as blood pressure, and to provide patients and their medical professionals with treatment plans for chronic disease management.


CSE:PMED - Post by User

Predictmedix AI Inc > Cannabis Impairment Clinical Study - 3,000+ people
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by MoneyShot19on Jun 29, 2020 12:10pm
100 Views
Post# 31203375

RE:Cannabis Impairment Clinical Study - 3,000+ people

RE:Cannabis Impairment Clinical Study - 3,000+ peopleI'd say a completed clinical study is material news that shareholders should be privy to, so would it be more accurate to say the results look to be positive and it is expected to be successful in the near future? Hence why TEch Mahindra has signed on and is perhaps getting a head start?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities